Combination of PD-1 Inhibitor and Chemoradiotherapy in Ovarian Cancer Patients
Overview
This case study investigates the efficacy of PD-1 inhibitors combined with chemotherapy and specific targeted therapies in ovarian cancer patients with brain metastases. Results indicate that while patients with single brain metastases may achieve long-term survival, those with multiple metastases face a poor prognosis.
Background
Ovarian cancer with brain metastases poses significant treatment challenges due to the limited efficacy of current therapies and the poor prognosis associated with brain involvement. The incidence of brain metastases in ovarian cancer patients is notable, and the development of effective treatment strategies is critical for improving patient outcomes. Immune checkpoint inhibitors, particularly PD-1 inhibitors, have emerged as potential therapeutic options, warranting investigation in this context.
Data Highlights
No numerical data was provided in the source material.
Key Findings
1. Patient with a single brain metastasis achieved complete response after comprehensive treatment.
2. Significantly prolonged progression-free survival was noted in the patient with a single brain metastasis.
3. The patient with multiple brain metastases showed short-term efficacy but ultimately died due to complications.
4. Higher expression of immune markers (CD4, CD8, CD31, PD-L1) was observed in brain metastases compared to primary tumors.
5. Gene testing confirmed homologous recombination repair deficiency (HRD) in the patient with a single brain metastasis.
6. Combination therapy with PARP inhibitors and PD-1 inhibitors was effective in the first patient.
Clinical Implications
The findings suggest that PD-1 inhibitors combined with chemotherapy and targeted therapy may offer a new treatment avenue for ovarian cancer patients with brain metastases, especially those with a single metastasis. Clinicians should consider the immune microenvironment characteristics, such as PD-L1 expression and T-cell infiltration, when evaluating treatment options for these patients.
Conclusion
The combination of PD-1 inhibitors with chemoradiotherapy presents a promising strategy for treating ovarian cancer patients with brain metastases, although the prognosis remains poor for those with multiple metastases. Further research is essential to explore the correlation between peripheral blood immune markers and treatment response in brain metastases.
